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Primary aldosteronism is the most common type of secondary hypertension affecting 6-10% of 2 
patients with primary hypertension.  PA is mainly caused by unilateral hyperaldosteronism due 3 
to an aldosterone-producing adenoma, unilateral hyperplasia with or without micronodules or 4 
bilateral zona glomerulosa hyperplasias with or without macro or micronodules. The 5 
development of antibodies against the terminal enzyme of aldosterone biosynthesis (CYP11B2)  6 
has permitted the further characterization of normal adrenals and resected adrenals from 7 
patients with primary aldosteronism. Normal adrenals exhibit two different patterns of cellular 8 
expression of CYP11B2: young individuals display a relatively uniform expression of the 9 
enzyme throughout the zona glomerulosa while the adrenals of older individuals have dispersed 10 
CYP11B2-expressing cells but have more groups of cells called aldosterone-producing cell 11 
clusters.  APAs exhibit different patterns of CYP11B2 staining that vary from uniform to 12 
homogeneous.  There is also a proportion of cells within the APA that co-express different 13 
enzymes that are not normally co-expressed in normal individuals.  Approximately 30% of 14 
patients with unilateral hyperaldosteronism do not have an APA, but either have an increased 15 
number of CYP11B2 expressing micronodules or hyperplasia of the zona glomerulosa.  16 
 3 
INTRODUCTION 17 
Primary aldosteronism (PA) is the most common form of secondary hypertension with a 18 
prevalence of 5-10% of patients with primary hypertension [1] and is associated with a 19 
significant increase in morbidity and mortality [2,3]. There are multiple forms of PA that present 20 
as sporadic cases and the two most common are aldosterone-producing adenomas (APA) and 21 
bilateral zona glomerulosa hyperplasia with micro- or with macronodules or with both micro- and 22 
macronodules, also called idiopathic hyperaldosteronism (IHA). Less common is unilateral zona 23 
glomerulosa hyperplasia with micro- and/or macronodules. Familial forms are rare and there are 24 
at least 4 different familial types of hyperaldosteronism which include Type 1 (also called 25 
glucocorticoid-suppressible aldosteronism) due to a crossover recombination of the promoter 26 
region and first exons of the CYP11B1 gene and the late exons of the CYP11B2 gene resulting 27 
in the production of aldosterone in the zona fasciculata (ZF) under ACTH control [4].  Type 2 is 28 
the most common form, but the genetic basis has not been elucidated, although there is a 29 
linkage to chromosome 7p22 in some families [5]. Type 3 is due to mutations in the KCNJ5 30 
gene encoding the GIRK4 potassium channel and alter the selectivity filter of the channel pore 31 
[6]. Type 4 is due to mutations in the CACNA1H gene encoding Cav3.2 a voltage activated 32 
calcium channel subunit [7]. 33 
The biosynthesis of aldosterone occurs in the adrenal zona glomerulosa (ZG) through a series 34 
of enzymatic reactions starting from cholesterol.  Most of the enzymes involved in aldosterone 35 
biosynthesis are also expressed in the ZF but the terminal enzyme, CYP11B2, is only 36 
expressed in the ZG and CYP11B1 is only expressed in the ZF [8,9]. The expression and 37 
distinct distribution of these two enzymes is shared by multiple species including humans, rats, 38 
mice, hamsters and guinea pigs [8,10]. Some species, such as cows, sheep, pigs, dogs and 39 
bullfrogs, express only a single CYP11B enzyme [8,11]; despite this,, aldosterone biosynthesis 40 
is restricted to the ZG as in species with two distinctly distributed enzymes [12]. The 41 
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mechanisms by which aldosterone production is suppressed in the ZF in species with a single 42 
CYP11B enzyme is unclear.  The human CYP11B2 and CYP11B1 are highly homologous at the 43 
DNA (95% in the coding region) and at the protein level (93%) [13].  The presence of CYP11B2 44 
identifies the cells of the adrenal that produce aldosterone.  In the human adrenal the ZF has 45 
two unique enzymes, the CYP17A1 and the CYP11B1 which are responsible for the synthesis 46 
of cortisol [8].  The first specific polyclonal antibodies against CYP11B1 and CYP11B2 were 47 
described by Nishimoto and were more suitable for low amplification immunohistochemistry 48 
[14]. Highly specific monoclonal antibodies were then described [15] and have been extensively 49 
used to define the immunohistochemistry of normal adrenals and of resected adrenals from 50 
patients with PA [16-19]. 51 
Zona glomerulosa in normal adrenals from rodents and humans. The rat adrenal has a clearly 52 
delineated zonation. The ZG (with CYP11B2 expression) comprises 4-6 layers of cells 53 
underneath the outer capsule that are separated from the ZF by a layer that comprises 54 
progenitor cells called the undifferentiated cell zone (without CYP11B1 or CYP11B2 expression) 55 
[20].  The number of cells in the ZG that express CYP11B2 depends on the degree and duration 56 
of stimulation by the renin-angiotensin system and on a normal salt diet about half the cells 57 
express CYP11B2 and they are scattered throughout the ZG [21]; a chronic low sodium diet 58 
increases the layers of cells and most cells express CYP11B2 [21].  The human adrenal does 59 
not have a similar clear-cut separation of the ZG and ZF and cells with CYP11B2 expression 60 
are present in scattered cells in the subcapsular region (Fig 1A) [22] and in clusters that have 61 
been called variously as aldosterone-producing cell clusters (APCC) [14,15], foci and megafoci 62 
depending on the size of the cell cluster [23] (Fig 1B).  These clusters show strong, uniform 63 
immunoreactivity for CYP11B2 with a ZG morphology that extends into the ZF, with no 64 
expression of CYP11B1. Adrenals from individuals from 0-11 years show a clear layered 65 
zonation with CYP11B2 expression that occupies a significant portion of the ZG and in some 66 
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cases there is an unstained layer between ZG labeled CYP11B2 and ZF labeled CYP11B1 and 67 
no APCC are found [22].  This layered arrangement remodels with age with significant portions 68 
of the ZG displaying low CYP11B2 expression while the APCC numbers increase  [22,24].  In 69 
rare cases a portion of the APCC toward the ZF show an apparent remodeling to CYP11B2 70 
expressing cells with ZF phenotype [22].  This pattern has been found in some patients with PA 71 
[25], but no clinical data was available in this study of supposed normal individuals [22].  In 72 
addition, cells expressing CYP11B1, which define the ZF can reach the capsule in some areas 73 
[15].   74 
Aldosterone-producing adenomas.   A significant advance in the pathogenesis of APAs was the 75 
discovery of somatic mutations in the selectivity filter of the G protein activated inward rectifier 76 
potassium channel GIRK4 coded by the KCNJ5 gene [6], which has been shown to be present 77 
in 35-70% of patients [26-28]. The higher percentage was found in individuals of east Asia 78 
[26,28,29].  Mutations in pumps including the sodium potassium ATPase alpha subunit 1 79 
(ATP1A1 gene), membrane calcium ATPase (ATP2B3 gene) and the calcium channel subunit 80 
Cav1.3 (CACNA1D gene) were then described in other cases  [7,30-32] and all together these 81 
mutations explain approximately 50-80% of cases of APA. Some cases of unilateral aldosterone 82 
hyperproduction have multiple nodules that express the CYP11B2 enzyme  and can have 83 
different mutated channels or pumps within the same gland [16,33,34].  APCCs from normal 84 
adrenals have an incidence of CACNA1D and ATP1A1 mutations as high as 30%, but APCCs 85 
with KCNJ5 mutations have not been detected [17].  It is unclear if APCCs harboring the 86 
mutations can develop into an aldosterone-producing adenoma. 87 
Immunohistochemistry in primary aldosteronism.  Adrenal vein catheterization is used to 88 
determine which is the abnormal adrenal producing the excessive amount of aldosterone. In 89 
most cases, unilateral aldosterone production is produced by an APA usually greater than 0.7 90 
cm in diameter that is visible by a computerized tomography scan. Many adrenals with a clear 91 
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adenoma frequently also have APCCs present in the hyperplastic ZG [35,36].In 30% of cases a 92 
microadenoma which is not visible by imaging techniques [37], unilateral ZG hyperplasia  with or 93 
without micro- or macro-nodules [37] and rare cases of aldosterone-producing carcinomas 94 
which are of larger size can occur [16].   95 
Large or small APAs can have two different phenotypic cell characteristics, more common are 96 
those with clear cells containing lipid droplets similar to ZF-type cells whereas other have more 97 
compact cells similar to ZG-type cells and a mixture of both types [38].  Some studies have 98 
correlated the cell type with the somatic mutation present in the APA and those with clear ZF 99 
cells tend to have KCNJ5 mutations while those with ATP1A1, ATP2B3 and CACNA1D 100 
mutations tend to be of the ZG type phenotype [31,38,39]. However other studies have not 101 
confirmed these results and although many APA carrying a KCNJ5 mutation have a ZF cell 102 
phenotype almost an equal number have a mixture of ZG and ZF type cells [27,38]. 103 
Aldosterone production in patients with larger adenomas is generally higher than in those 104 
patients with smaller adenomas [40]. In the study by Ono et al [40], the tumor area of the group 105 
of larger adenomas was 9 times greater than the group of smaller adenomas but plasma 106 
aldosterone concentrations were only 2.0-2.5 times increased in the group of patients with the 107 
larger APA. This indicated that aldosterone production per cell was much greater from smaller 108 
adenomas, a suggestion that was supported by the higher immunoreactivity of CYP11B2 109 
observed in the smaller group of tumors[40] . The number of  CYP11B2 immunoreactive cells in 110 
the larger adenomas was highly variable with some adenomas displaying a relatively uniform 111 
expression of CYP11B2 (Fig 1C) compared to a heterogeneous expression of the enzyme in 112 
others with many cells that were immunoreactive negative (Fig 1D). The immunoreactivity of 113 
other enzymes including the CYP17A1 was lower in the smaller adenomas [40]. Outcomes after 114 
adrenalectomy for patients with smaller or larger APAs were similar between the two groups 115 
[40].   116 
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Many APAs exhibit an intratumoral heterogeneity of expressed enzymes that are normally 117 
specific to a distinct zone of the adrenal. In a recent study using double and triple 118 
immunofluorescence staining of APAs with antibodies against CYP11B2, CYP11B1 and 119 
CYP17A1, Nakamura et al [41] demonstrated that there are cells co-expressing the CYP11B2 120 
and CYP11B1 (2.1%), CYP11B2 and CYP17A1 (0.6%), CYP11B1 and CYP17A1 (0.6%) and a 121 
smaller number of triple immunoreactive stained cells (0.14%).  However, the proportions of the 122 
different immunofluorescent mixed cells were highly variable between adenomas.  The 123 
presence of cells that co-express the CYP11B2 and CYP17A1 probably explains the increased 124 
secretion of the hybrid steroids 18-hydroxycortisol and 18-oxocortisol [42]. 125 
The increased use of AVS has enabled the diagnosis of unilateral aldosterone production in 126 
image negative patients that occurs in about 30% of patients with unilateral PA [43,44]. 127 
Immunohistochemistry studies of the resected adrenals from 32 patients with PA operated due 128 
to unilateral (or in 6 cases bilateral) production of aldosterone studied using CYP11B2 staining 129 
showed that 19 of those with an adenoma showed CYP11B2 staining in the adenoma, 1 patient 130 
with an adenoma and 3 cases of bilateral production of aldosterone with a unilateral adenoma, 131 
the adenoma did not stained for the CYP11B2 but had had multiple APCCs and 2 specimens 132 
had multiple micronodules with diffuse ZG hyperplasia staining for the CYP11B2 enzyme [35].  133 
Of the 9 patients without a tumor on CT, 6 had unilateral aldosterone production and 3 were 134 
bilateral. Of the unilateral aldosterone producers, 3 had a microadenoma and 1 had multiple 135 
micronodules staining for the CYP11B2 [35]. Of the 3 showing no tumors, but bilateral 136 
production of aldosterone 2 had multiple APCCs and 1 diffuse hyperplasia [35].  In a recent 137 
study of 25 adrenals with histopathology of cross-sectional image negative hyperaldosteronism 138 
they were classified into two types 13 had multiple adrenocortical micronodules and 12 had 139 
diffuse hyperplasia of the zona glomerulosa [16].  Somatic mutations of aldosterone-driver 140 
genes were detected in 81% of CYP11B2-positive micronodules with 65% had mutations of the 141 
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CACNA1D gene, 8% in the KCNJ5 gene and 4% in the ATP1A1 and ATP2B3 genes, but no 142 
mutations were found in the CYP11B2-positive non-nodular areas [16].    143 
The possibility that the origin of an APA is from further differentiation of an APCC was recently 144 
postulated through the finding of cases where cells from an APCC expressing the CYP11B2 145 
changed morphologically from a compact cell phenotype characteristic of the ZG to a clear cell 146 
phenotype resembling ZF cells and these have been called possible APCC-to-APA transitional 147 
lesions some of which had KCNJ5 mutations [25]. 148 
Patients with APA or those with unilateral production of aldosterone have been the treated by 149 
unilateral adrenalectomy of the involved site with either cure or significant improvement of the 150 
hypertension and biochemical abnormalities of the PA and in fewer cases resulting in no 151 
improvement.  As no standard criterial for defining surgical outcomes was accepted, a recent 152 
study aimed to create a consensus criteria for outcomes [45].  The PASO study involved an 153 
international panel of 31 experts from 28 centers using the Delphi method to reach consensus. 154 
Complete clinical success correcting the hypertensionwas obtained in 37% of 705 patients with 155 
wide variance (17-62%) and partial success in 47% (range of 35-66%).  Complete biochemical 156 
success was seen in 94% of patients [45].  A distinction between an adenoma and a nodule is 157 
difficult histopathologically. The frequent presence of APCCs and complete contralateral 158 
suppression of aldosterone production in the contralateral adrenal let us before to postulate that 159 
many cases are of bilateral asymmetric hyperplasia with many of the ones described as an 160 
adenoma being instead a hyperplastic steroidogenically active nodule [46]. In summary, 161 
immunohistochemistry of the CYP11B2 enzyme that catalyzes last steps of aldosterone 162 
biosynthesis, has helped uncover a significant complexity in the histological features of the 163 
adrenals of patients with unilateral production of aldosterone.  Whereas the normal adrenal has 164 
a very distinctive pattern of expression of steroidogenic enzymes in the different zones, many 165 
adenomas undergo a disordered expression of the various steroidogenic enzymes with the 166 
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appearance of hybrid cells expressing a mixture of these enzymes.  The wide variation in 167 
histopathological features of the adenomas and concurrent presence of APCCs raise the 168 
possibility that most cases of unilateral production of aldosterone actually might represent 169 
bilateral asymmetric hyperplasia with nodules frequently due to the development of somatic 170 
aldosterone-driving mutations. 171 
  172 
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Legend: 185 
Figure 1.  Immunohistochemical staining of adrenals with the CYP11B2 antibody. A. Normal 186 
adrenal from a young individual showing diffuse staining in the subcapsular area.  B.  Normal 187 
adrenal of an older individual showing an aldosterone-producing cell cluster.  C. APA showing 188 
fairly uniform staining of the whole adenoma. C. APA showing uneven staining of the adenoma.  189 
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